Needham Reiterates Buy on Nurix Therapeutics, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a price target of $29.
October 14, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics and maintained a price target of $29, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $29 price target by a reputable analyst suggests a positive outlook for Nurix Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100